nach oben

Reactions Weekly

Erschienen in:

01.06.2018 | Case report

Cabergoline

Dizziness and nausea: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In a single-centre retrospective study that included 82 patients, one patient [age and sex not stated] was described, who developed nausea and dizziness during treatment with cabergoline for acromegaly [dosage, route, duration of treatment to reactions onsets and outcomes not stated]. The patient, who had acromegaly, started receiving treatment with cabergoline and first-generation somatostatin receptor ligands [specific drug not stated]. However, the patient was not able to tolerate cabergoline due to nausea and dizziness. Therefore, cabergoline was discontinued. …

Kasuki L, et al. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clinical Endocrinology 88: 889-895, No. 6, Jun 2018. Available from: URL: http://doi.org/10.1111/cen.13595 - BrazilCrossRefPubMed

Titel: Cabergoline
Dizziness and nausea: case report
Publikationsdatum: 01.06.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-48179-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cabergoline

Dizziness and nausea: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Imatinib/sunitinib

Colistin/tigecycline

Antibacterials/immunosuppressants

Ciclosporin

Pegaspargase

Adalimumab/infliximab